<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577469</url>
  </required_header>
  <id_info>
    <org_study_id>827-2018</org_study_id>
    <nct_id>NCT04577469</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Sulfadoxine/ Pyrimethamine Tablets in Healthy Subjects Under Fasting Conditions</brief_title>
  <official_title>Randomized,One-period,Single Oral Dose,Open-label,Parallel,Bioequivalence Study to Compare 500mg Sulfadoxine/25mg Pyrimethamine Tablet Versus G-COSPE® Tablet (500mg Sulfadoxine/25mg Pyrimethamine) in Healthy Subjects Under Fasting Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emzor Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emzor Pharmaceutical Industries Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To asses bio equivalence between two (500 mg sulfadoxine / 25 mg pyrimethamine) formulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to assess bioequivalence between a single dose from the test&#xD;
      product, Sulfadoxine/ Pyrimethamine tablets (500 mg sulfadoxine / 25 mg pyrimethamine),&#xD;
      manufactured by Ms. Emzor Pharmaceuticals Industries Ltd, Nigeria versus the reference&#xD;
      product G-COSPE® tablets (500 mg sulfadoxine / 25 mg pyrimethamine) manufactured by Guilin&#xD;
      Pharmaceutical Co. Ltd, China under fasting conditions and to monitor the safety of the&#xD;
      subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Peak Plasma Concentration (Cmax) for Sulfadoxine and Pyrimethamine.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The average bioequivalence of the products will be concluded if the two-sided 90 % confidence interval for the test to reference ratio of the population means is within 80.00 - 125.00 % for the ln transformed data Cmax of sulfadoxine &amp; pyrimethamine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curves (AUC0 - 72) for Sulfadoxine and Pyrimethamine.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The average bioequivalence of the products will be concluded if the two-sided 90 % confidence interval for the test to reference ratio of the population means is within 80.00 - 125.00 % for the ln transformed data AUC0 -72 of sulfadoxine &amp; pyrimethamine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Obtaining the Tmax (Time to reach maximum concentration) for Sulfadoxine and Pyrimethamine</measure>
    <time_frame>12 weeks</time_frame>
    <description>The descriptive statistics including Maximum, Minimum and Median values will be measured for Tmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG QTc Interval (safety and tolerability)</measure>
    <time_frame>ECG recording will be performed 4 hours post- dosing and at the end of the study (at 72.00 hours post dosing) as follow-up tests</time_frame>
    <description>Clinically significant abnormal deviations in ECG QTc interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (safety and tolerability)</measure>
    <time_frame>At 1-hour pre-dosing; 2, 4, 6, 8, 12 and 23 hours post-dosing (±45 minutes of scheduled time). Blood pressure will also be measured at 48 and 72 hours post-dosing upon ambulatory sample collection.</time_frame>
    <description>Clinically significant abnormal deviations. Normal range of blood pressure &gt; 90/60 and &lt;140/90 mmHg. Treatment will be offered to those subjects whom blood pressure drops to 90/60 mm Hg or less and the subject will be excluded in case of not responding to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse (safety and tolerability)</measure>
    <time_frame>At 1-hour pre-dosing; 2, 4, 6, 8, 12 and 23 hours post-dosing (±45 minutes of scheduled time). Pulse will also be measured at 48 and 72 hours post-dosing upon ambulatory sample collection.</time_frame>
    <description>Clinically significant abnormal deviations. Normal range of Pulse 60-100 Bpm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature (safety and tolerability)</measure>
    <time_frame>At 1-hour pre-dosing; 2, 6, 10, 14, 18, 22 &amp; 23 hours post-dosing (±45 minutes of scheduled time). Temperature will also be measured at 48 and 72 hours post-dosing upon ambulatory sample.</time_frame>
    <description>Clinically significant abnormal deviations. The temperature will be measured axillary, orally or using infrared thermometer, standardized across all subjects. Normal range of temperature 36.5-37.5 ºC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate (safety and tolerability)</measure>
    <time_frame>At 1-hour pre-dosing; 2, 6, 10, 14, 18, 22 &amp; 23 hours post-dosing (±45 minutes of scheduled time). Respiratory rate will also be measured at 48 and 72 hours post-dosing upon ambulatory sample.</time_frame>
    <description>Clinically significant abnormal deviations. Normal range of respiratory rate 12-18 B/M</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology (Safety and Tolerability)</measure>
    <time_frame>At the end of the study (at 72.00 hours post dosing)</time_frame>
    <description>Hematology test will include Complete blood count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With AEs</measure>
    <time_frame>At 12 and 1-hour pre-dosing; 2, 4, 6, 8, 10, 12, 23, 48 and 72 hours post-dosing</time_frame>
    <description>Safety and tolerability: number of subjects with adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>500 mg sulfadoxine / 25 mg pyrimethamine tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg sulfadoxine / 25 mg pyrimethamine tablet will be administered once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-COSPE® tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>G-COSPE® tablets (500 mg sulfadoxine / 25 mg pyrimethamine) will be administered once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maldox tablets</intervention_name>
    <description>500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition</description>
    <arm_group_label>500 mg sulfadoxine / 25 mg pyrimethamine tablet</arm_group_label>
    <arm_group_label>G-COSPE® tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-COSPE® tablets</intervention_name>
    <description>500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition</description>
    <arm_group_label>500 mg sulfadoxine / 25 mg pyrimethamine tablet</arm_group_label>
    <arm_group_label>G-COSPE® tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. The subject is aged between eighteen &amp; fifty years (18 - 50).&#xD;
&#xD;
          2. The subject is within the limits for his height &amp; weight as defined by the body mass&#xD;
             index range (18.5 - 30.0 Kg/m2).&#xD;
&#xD;
          3. The subject is willing to undergo the necessary pre- &amp; post- medical examinations set&#xD;
             by this study.&#xD;
&#xD;
          4. Results of medical history, vital signs, physical examination &amp; conducted medical&#xD;
             laboratory tests are normal as determined by the clinical investigator.&#xD;
&#xD;
          5. The subject tested negative for hepatitis (B &amp; C) viruses and human immunodeficiency&#xD;
             virus (HIV).&#xD;
&#xD;
          6. There is no history or evidence of psychiatric disorder, antagonistic personality, and&#xD;
             poor motivation, emotional or intellectual problems likely to limit the validity of&#xD;
             consent to participate in the study or limit the ability to comply with protocol&#xD;
             requirements.&#xD;
&#xD;
          7. The subject is able to understand and willing to sign the informed consent form.&#xD;
&#xD;
          8. The subject has normal liver (AST &amp; ALT enzymes) function.&#xD;
&#xD;
          9. The subject's kidney function tests are within normal ranges.&#xD;
&#xD;
         10. The subject has normal respiratory system.&#xD;
&#xD;
         11. The subject has normal platelet levels.&#xD;
&#xD;
         12. For female subjects: negative pregnancy test and the woman is using two reliable&#xD;
             contraception methods.&#xD;
&#xD;
         13. The subject has normal cardiovascular system, ECG recording &amp; QTc interval less than&#xD;
             450 ms.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. The subject is a heavy smoker (more than 10 cigarettes per day).&#xD;
&#xD;
          2. The subject has suffered an acute illness one week before dosing.&#xD;
&#xD;
          3. The subject has a history of or concurrent consumption of alcohol.&#xD;
&#xD;
          4. The subject has a history of or concurrent consumption of illicit drugs.&#xD;
&#xD;
          5. The subject has a history of hypersensitivity and/or contraindications to the study&#xD;
             drug and any related compounds.&#xD;
&#xD;
          6. Subject who has been hospitalized within three months before the study or during the&#xD;
             study.&#xD;
&#xD;
          7. Subject who is vegetarian.&#xD;
&#xD;
          8. The subject has consumed caffeine or xanthine containing beverages or foodstuffs&#xD;
             within two days before dosing and until 23 hours after dosing.&#xD;
&#xD;
          9. The subject has taken a prescription medication within two weeks or even an over the&#xD;
             counter product (OTC) within one week before dosing and any time during the study,&#xD;
             unless otherwise judged acceptable by the clinical investigator.&#xD;
&#xD;
         10. The subject has taken grapefruit containing beverages or foodstuffs within seven (7)&#xD;
             days before first dosing and any time during the study.&#xD;
&#xD;
         11. The subjects who have been participating in any clinical study (e.g. pharmacokinetics,&#xD;
             bioavailability and bioequivalence studies) within the last 80 days prior to the&#xD;
             present study&#xD;
&#xD;
         12. The subjects who have donated blood within 80 days before first dosing.&#xD;
&#xD;
         13. The subject has a history presence of cardiovascular, pulmonary, renal, hepatic,&#xD;
             gastrointestinal, hematological, endocrinal, immunological, dermatological,&#xD;
             neurological, musculoskeletal or psychiatric diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed A Abu Fara, MD,Internist</last_name>
    <role>Principal Investigator</role>
    <affiliation>ACDIMA Biocenter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rabab F Tayyem, PhD</last_name>
    <phone>+ 962 79 5616375</phone>
    <email>rabab@acdima.com</email>
  </overall_contact>
  <link>
    <url>https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf</url>
    <description>ICH E6(R2) guideline</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

